Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory … – GlobeNewswire (press release)
|
Sorrento and Celularity to Start Anti-CD38 CAR–T Phase 1 Clinical Trial in Patients With Relapsed or Refractory …
GlobeNewswire (press release) SAN DIEGO, April 05, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) and Celularity Inc announced today that the companies have started screening patients for its leading CD38 chimeric antigen receptor (CAR) T cell therapy drug … |
